Summary
Zolpidem is an imidazopyridine which differs in structure from the benzodiazepines and zopiclone. It is a strong sedative with only minor anxiolytic, myorelaxant and anticonvulsant properties, and has been shown to be effective in inducing and maintaining sleep in adults. The available evidence suggests that zolpidem produces no rebound or withdrawal effects, and patients have experienced good daytime alertness. Zolpidem 10mg in non-elderly and a reduced dose of 5mg in elderly individuals are clinically effective.
In humans, the major metabolic routes include oxidation and hydroxylation; none of the metabolites appears to be pharmacologically active. The pharmacological activity of zolpidem results from selective binding to the central benzo-diazepine receptors of the ωl subtype.
Zolpidem is approximately 92% bound to plasma proteins; absolute bioavailability of zolpidem is about 70%. After single 20mg oral doses, typical values of pharmacokinetic variables for zolpidem in humans are: a peak plasma concentration of 192 to 324 µg/L occurring 0.75 to 2.6 hours postdose; a terminal elimination half-life of 1.5 to 3.2 hours; and total clearance of 0.24 to 0.27 ml/min/kg. Zolpidem pharmacokinetics are unchanged during multiple-dose treatment.
Zolpidem pharmacokinetics are not significantly influenced by gender. Clearance of zolpidem in children is 3 times higher than in young adults, and is lower in very elderly people. There are no significant differences in the pharmacokinetic parameters between various racial groups. Dosage reduction appears to be prudent in patients with renal disease, and caution should be exercised when prescribing zolpidem to elderly patients with hepatic impairment.
Coadministration of haloperidol, cimetidine, ranitidine, chlorpromazine, warfarin, digoxin or flumazenil do not alter the pharmacokinetics of zolpidem; flumazenil predictably antagonises the hypnotic effects of zolpidem. Alertness tends to be reduced when cimetidine is combined with zolpidem. Volunteers treated with imipramine plus zolpidem developed anterograde amnesia.
Similar content being viewed by others
References
George P, Rossey G, Depoortere H, et al. Zolpidem and related compounds: syntheses, physical properties and structure-activity relationships. In: Sauvanet JP, Langer SZ, Morselli PL, editors. Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach. New York: Raven Press, 1988: 11–23
Durand A, Thénot JP, Bianchetti G, et al. Comparative pharmacokinetic profile of two imidazopyridine drugs: zolpidem and alpidem. Drug Metab Rev 1992; 24: 239–66
Merlotti L, Roehrs T, Koshorek G, et al. The dose effects of zolpidem on the sleep of healthy normals. J Clin Psychopharmacol 1989; 9: 9–14
Nicholson AN, Pascoe PA. Hypnotic activity of an imidazo-pyridine (zolpidem). Br J Clin Pharmacol 1986; 21: 205–11
Lund R, Rüther E, Wober W, et al. Effects of zolpidem (10 and 20 mg), lormetazepam, triazolam, and placebo on night sleep and residual effects during the day. In: Sauvanet JP, Langer SZ, Morselli PL, editors. Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach. New York: Raven Press, 1988: 193–203
Oswald I, Adam K. A new look at short-acting hypnotics. In: Sauvanet JP, Langer SZ, Morselli PL, editors. Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach. New York: Raven Press, 1988: 253–9
Blois R, Gaillard JM. The effects of zolpidem on the characteristics of normal sleep. In: Sauvanet JP, Langer SZ, Morselli PL, editors. Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach. New York: Raven Press, 1988: 375–6
Langtry HD, Benfield P. Zolpidem: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 1990; 40: 291–313
Langer SZ, Arbilla S, Scatton B, et al. Receptors involved in the mechanism of action of zolpidem. In: Sauvanet JP, Langer SZ, Morselli PL, editors. Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach. New York: Raven Press, 1988: 55–70
Langer SZ, Arbilla S. Imidazopyridines as a tool for characterization of benzodiazepine receptors: A proposal for a pharmacological classification as omega receptor subtypes. Pharmacol Biochem Behav 1988; 29: 763–6
Biggio G, Concas A, Corda MG, et al. Enhancement of GABA-ergic transmission by zolpidem, an imidazopyridine with preferential affinity for type I benzodiazepine receptors. Eur J Pharmacol 1989; 161: 173–80
Zivkovic B, Perrault G, Morel E, et al. Comparative pharmacology of zolpidem and other hypnotics and sleep inducers. In: Sauvanet JP, Langer SZ, Morselli PL, editors. Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach. New York: Raven Press, 1988: 97–109
Pons G, Francoual C, Guillet Ph, et al. Zolpidem excretion in breast milk. Eur J Clin Pharmacol 1989; 37: 245–8
Thénot JP, Hermann P, Durand A, et al. Pharmacokinetics and metabolism of zolpidem in various animal species and in humans. In: Sauvanet JP, Langer SZ, Morselli PL, editors. Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach. New York: Raven Press, 1988: 139–53
Bianchetti G, Dubruc C, Thiercelin JP, et al. Clinical pharmacokinetics of zolpidem in various physiological and pathological conditions. In: Sauvanet JP, Langer SZ, Morselli PL, editors. Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach. New York: Raven Press, 1988: 155–63
Hohens JD, Perry PJ. Zolpidem: A nonbenzodiazepine hypnotic for treatment of insomnia. Clin Pharm 1993; 12: 814–28
Pacifici GM, Viani A, Rizzo G, et al. Plasma protein binding of zolpidem in liver and renal insufficiency. Int J Clin Pharmacol Therapeut Toxicol 1988; 26: 439–43
Guinebault P, Dubruc C, Hermann Ph, et al. High-performance liquid Chromatographie determination of zolpidem, a new sleep inducer, in biological fluids with fluorimetric detection. J Chromatogr 1986; 383: 206–11
Ascalone V, Flaminio L, Guinebault P, et al. Determination of zolpidem, a new sleep-inducing agent, and its metabolites in biological fluids: pharmacokinetics, drug metabolism and overdosing investigations in humans. J Chromatogr 1992; 581: 237–50
Albin H, Vinçon G, Vinçon J, et al. Study of the pharmacokinetics of zolpidem in healthy volunteers after repeated administration: Effect on antipyrine clearance. In: Sauvanet JP, Langer SZ, Morselli PL, editors. Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach. New York: Raven Press, 1988: 369–70
Desager JP, Hulhoven R, Harvengt C, et al. Possible interaction between zolpidem, a new sleep inducer, and chlorpromazine, a phenothiazine neuroleptic. Psychopharmacology 1988; 96: 63–6
Vandel S, Vandel B, Joanne C, et al. Influence of ethnic origin on the clinical pharmacology of zolpidem. In: Sauvanet JP, Langer SZ, Morselli PL, editors. Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach. New York: Raven Press, 1988: 390–1
Colle M, Rosenzweig P, Bianchetti G, et al. Nocturnal profile of growth hormone secretion during sleep induced by zolpidem: A double-blind study in young adults and children. Horm Res 1991; 35: 30–4
Patat A, Trocherie S, Thebault JJ, et al. EEG profile of intravenous zolpidem in healthy volunteers. Psychopharmacology 1994; 114: 138–46
Priest RG. Ambieu (zolpidem 5 mg & 10 mg). UK product licence application. Paris: Registration Department (L.E.R.S.), 1993
Harvengt C, Hulhoven R, Desager JP, et al. Drug interactions investigated with zolpidem. In: Sauvanet JP, Langer SZ, Morselli PL, editors. Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach. New York: Raven Press, 1988: 165–73
Hulhoven R, Desager JP, Harvengt C, et al. Lack of interaction between zolpidem and H2 antagonist, cimetidine and ranitidine. Int J Clin Pharmacol Res 1988; 8: 471–6
Danjou P, Forster A, Rosenzweig P, et al. Assessment of pharmacodynamic and pharmacokinetic interactions between intravenous zolpidem and flumazenil in healthy subjects. Biol Psychiatry 1991; 29: 456S–7S
Kanno O, Watanabe H, Ichikawa I, et al. Effects of zolpidem and triazolam on all night sleep EEG of normal volunteers. Biol Psychiatry 1991; 29: 305S
Scharf MB, Mayleben DW, McDannold MD, et al. Dose response effects of zolpidem in normal geriatric patients. Sleep Res 1988; 17: 59
Morselli PL, Larribaud J, Guillet Ph, et al. Daytime residual effects of Zolpidem: a review of available data. In: Sauvauet JP, Lauger SZ, Morselli PL, editors. Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach. New York: Raven Press, 1988: 183–91
Gillin JC. Rebound insomnia: a critical review. J Clin Psychopharmacol 1989; 9: 161–72
Kales A. Rebound insomnia and rebound anxiety: a review. Pharmacology 1983; 26: 121–37
Jonas JM. Idiosyncratic side effects of short half-life benzodiazepine hypnotics: fact or fancy? Hum Psychopharmacol 1992; 7: 205–16
Cirignotta F, Mondini S, Zucconi M, et al. Zolpidem-poly-somnographic study of the effect of a new hypnotic drug in sleep apnoea syndrome. Pharmacol Biochem Behav 1988; 29: 807–9
Kurtz D, Fillius B, Boningen C, et al. Effect of zolpidem on the sleep of healthy elderly subjects: polysomnographic recording assessments and pharmacokinetics. In: Sauvanet JP, Langer SZ, Morselli PL, editors. Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach. New York: Raven Press 1988: 382
Scharf MB, Mayleben DW, Kaffeman M, et al. Dose response effects of zolpidem in normal geriatric subjects. J Clin Psychiatry 1991; 52: 77–83
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Salvà, P., Costa, J. Clinical Pharmacokinetics and Pharmacodynamics of Zolpidem. Clin-Pharmacokinet 29, 142–153 (1995). https://doi.org/10.2165/00003088-199529030-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199529030-00002